Severe infection, and prolonged hospital/ICU stay were higher in COVID19 patients with underling CLD. Monitoring of those high risk patients and tailoring of their therapeutic approaches is a matter of worry increasing their diagnostic and therapeutic burden.Patients with underlying comorbidity may have serious outcome and hepatic comorbidity is an important one of these comorbidities and this representing the outcome of this study.